FDA Role In Prioritizing Pediatric Oncologic Development On Cmte. Agenda
Executive Summary
FDA's Pediatric Oncology Subcommittee should consider whether the agency should contribute to the prioritization of development of pediatric oncologic therapies, participants in FDA's workshop on pediatric oncology drug development agreed
You may also be interested in...
Global Consortium Would Facilitate Early Pediatric Oncology Trials – Cmte.
An international research consortium should be established to facilitate the conduct of Phase I-II trials of pediatric oncology drugs in the U.S. and other countries, members of FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee said at its July 15 meeting
Global Consortium Would Facilitate Early Pediatric Oncology Trials – Cmte.
An international research consortium should be established to facilitate the conduct of Phase I-II trials of pediatric oncology drugs in the U.S. and other countries, members of FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee said at its July 15 meeting
Pediatric Oncology Subcmte. Should Discuss Timing Of Studies – Workshop
The Pediatric Oncology Subcommittee should determine when it is appropriate to initiate clinical testing of oncologic agents in children, participants at an FDA workshop on pediatric oncology drug development agreed